Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 12 of 23
May 12, 2026The landscape of employer benefits related to weight management medications like GLP-1s is evolving as financial pressures prompt reassessment of coverage policies. This shift could impact access and affordability for employees relying on these treatments.
Sophia Reynolds
May 12, 2026Bizengri, a bispecific antibody acquired from Merus, represents the first FDA-approved treatment targeting a molecular subset of cholangiocarcinoma characterized by ultra-rare NRG1 gene fusions. This milestone offers new hope for patients with limited therapeutic options due to the rarity and complexity of their cancer.
Michael Torres
May 8, 2026Eli Lilly is significantly expanding its manufacturing footprint in Indiana through a substantial $4.5 billion investment. This includes launching the Lilly Lebanon Advanced Therapies site, designed to accelerate the transition of cutting-edge genetic medicines from research phases into commercialization.
Dr. Priya Nandakumar
May 8, 2026Angelini Pharma has executed a transformative acquisition, purchasing Catalyst Pharmaceuticals to bolster its position in the rare disease therapeutic market. This acquisition aligns with Angelini's broader focus on neurological medicines and rare conditions, underpinned by Catalyst's FDA-approved drug Firdapse.
Michael Torres
May 7, 2026The biopharmaceutical landscape witnessed significant events this week including Seaport Therapeutics achieving a successful IPO, ongoing battles in the highly competitive obesity drug market, and political challenges surrounding the FDA commissioner affecting regulatory processes. This article explores these key developments and what they mean for the industry going forward.
Sophia Reynolds
May 7, 2026Despite ongoing efforts to revive Elevidys, Sarepta Therapeutics conveys a realistic and measured approach to its growth prospects, emphasizing the complexity and time required for sustained recovery in the gene therapy field.
Dr. Priya Nandakumar
May 6, 2026The acquisition centers around a mid-stage clinical program involving an innovative implant that controls drug release to treat severe eye conditions such as glaucoma and diabetic retinopathy. This strategic move by Bayer underscores the company’s commitment to advancing ophthalmologic therapies.
Jonathan Blake
May 6, 2026The biotechnology sector continues its gradual recovery, but founders face multi-dimensional pressures. From refining leadership skills to unconventional investor outreach, industry players are adapting to a transforming landscape.
Dr. Alex Morgan
May 5, 2026The integration of functional medicine into mainstream health insurance networks marks a pivotal shift in healthcare, potentially enhancing patient access and acceptance of holistic treatment models. Parsley Health’s recent agreements with several major insurance companies highlight this transformative trend, opening new avenues for treating chronic and complex conditions.
Daniel Cho
May 5, 2026While the first quarter results from Vertex Pharmaceuticals appear subdued, the biopharma sector anticipates a significant shift linked to its pipeline, particularly the transformative potential of povetacicept. This article delves into the renal therapy landscape and assesses the implications of upcoming regulatory milestones.
Dr. Alex Morgan
May 4, 2026In a strategic move to strengthen its position in autoimmune and immunology therapeutics, UCB has finalized the acquisition of Candid Therapeutics for $2.2 billion. The deal includes two clinical-stage T cell engagers aimed at resetting the immune system in autoimmune disorders. This acquisition reflects ongoing consolidation trends in pharma and highlights the increasing focus on innovative immune-targeted therapies.
Daniel Cho
May 4, 2026In response to supply chain challenges and rising demand in outsourced fill/finish services, PCI is more than doubling its capacity to fill prefilled syringes and cartridges for pharmaceuticals. This strategic expansion underscores the growing importance of sterile drug delivery technologies in the biopharma sector.
Dr. Priya NandakumarMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.